Actavis' Generic Suboxone® Receives FDA Approval

               Actavis' Generic Suboxone® Receives FDA Approval

PR Newswire

PARSIPPANY, N.J., Feb. 25, 2013

PARSIPPANY, N.J., Feb. 25, 2013 /PRNewswire/ --Actavis, Inc. (NYSE: ACT)
today announced that it has received approval from the U.S. Food and Drug
Administration (FDA) on its Abbreviated New Drug Application (ANDA) for
Buprenorphine HCl and Naloxone HCl Dihydrate SL Tablets, 2 mg/0.5 mg and 8
mg/2 mg, the generic equivalent to Reckitt Benckiser Healthcare's
Suboxone^®.

Actavis intends to begin shipping the product immediately. Suboxone^® is
indicated for maintenance treatment of opioid dependence.

For the 12 months ending December 31, 2012, Suboxone^® tablets had total U.S.
sales of approximately $625 million, according to IMS Health data.

About Actavis

Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical
company focused on developing, manufacturing and distributing generic, brand
and biosimilar products. The Company has global and U.S. headquarters in
Parsippany, New Jersey, USA, and international headquarters in Zug,
Switzerland.

Actavis is the world's third-largest generics prescription drug manufacturer.
Operating as Actavis Pharma, the Company develops, manufactures and markets
generic, branded generic, legacy brands and Over-the-Counter (OTC) products in
more than 60 countries. The Company is ranked in the top 3 in 12 global
markets, the top 5 in 16 global markets, and in the top 10 in 33 global
markets. Actavis Pharma also develops and out-licenses generic pharmaceutical
products outside the U.S. through its Medis third-party business, the world's
largest generic pharmaceutical out-licensing business. Medis has more than 300
customers globally, and offers a broad portfolio of more than 200 products.

Actavis Specialty Brands is the Company's global branded specialty
pharmaceutical business, which develops and markets a portfolio of
approximately 40 products principally in the United States and Canada that are
focused in the Urology and Women's Health therapeutic categories. Actavis
Specialty Brands is committed to developing and marketing biosimilars products
in Women's Health, Oncology and other therapeutic categories, and currently
has a portfolio of 5 biosimilar products in development.

Actavis Global Operations has more than 30 manufacturing and distribution
facilities around the world, with a capacity of approximately 44 billion units
annually. Actavis Global Operations also includes Anda, Inc., the
fourth-largest U.S. generic pharmaceutical product distributor in the United
States.

For press release and other company information, visit Actavis' Web site at
http://www.actavis.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts
are forward-looking statements that reflect Actavis' current perspective of
existing information as of the date of this release. It is important to note
that Actavis' goals and expectations are not predictions of actual
performance. Actual results may differ materially from Actavis' current
expectations depending upon a number of factors, risks and uncertainties
affecting Actavis' business. These factors include, among others, the impact
of competitive products and pricing; the timing and success of product
launches; difficulties or delays in manufacturing; the availability and
pricing of third party sourced products and materials; successful compliance
with FDA and other governmental regulations applicable to Actavis and its
third party manufacturers' facilities, products and/or businesses; changes in
the laws and regulations, including Medicare and Medicaid, affecting among
other things, pricing and reimbursement of pharmaceutical products; and such
other risks and uncertainties detailed in Actavis' periodic public filings
with the Securities and Exchange Commission, including but not limited to
Actavis' Quarterly Report on Form 10-Q for the quarter ended September 30,
2012 and Actavis' Annual Report on Form 10-K for the year ended December 31,
2011 (such periodic public filings having been filed under the "Watson
Pharmaceuticals, Inc." name). Except as expressly required by law, Actavis
disclaims any intent or obligation to update these forward-looking statements.
Suboxone^® is a registered trademark of Reckitt Benckiser Healthcare (UK) Ltd.

CONTACTS: Investors:
Lisa DeFrancesco
(862) 261-7152

Media:
Charlie Mayr
(862) 261-8030

(Logo: http://photos.prnewswire.com/prnh/20130124/NY47381LOGO )

SOURCE Actavis, Inc.

Website: http://www.actavis.com
 
Press spacebar to pause and continue. Press esc to stop.